Survivors (n = 148) | Non-survivors (n = 10) | P | |
---|---|---|---|
Demographic parameters | |||
Age, yrs | 57 (50–64) | 72 (68–80) | 0.0001 |
Gender (men,%) | 70 | 72 | 1.00 |
BMI (kg/m2) | 26.0 (24.1-28.0) | 25.0 (21.0-26.8) | 0.27 |
Medical history | |||
Hypertension,% | 45 | 45 | 1.00 |
Diabetes,% | 13 | 20 | 0.63 |
Smoking,% | 65 | 30 | 0.042 |
Previous angina,% | 20 | 70 | 0.0006 |
Prior MI,% | 9 | 0 | 0.60 |
Current disease | |||
Time to treatment, hrs | 3.5 (2.5-5.0) | 7.0 (4.0-9.0) | 0.003 |
Max. QRS duration, ms | 90 (80–100) | 100 (93–120) | 0.60 |
EF,% | 61 (50–72) | 56 (45–63) | 0.003 |
Killip-Kimball class >1,% | 3 | 64 | 0.0001 |
Angiographic parameters | |||
>1 vessel affected,% | 47 | 90 | 0.016 |
TIMI (0–2) before PCI,% | 93 | 100 | 1.00 |
TIMI (0–2) after PCI,% | 32 | 60 | 0.091 |
CTFG | 24 (30–32) | 25 (31–100) | 0.019 |
MBG (0–1),% | 32 | 60 | 0.091 |
Abciximab,% | 26 | 70 | 0.008 |
PCI complications,% | 5 | 40 | 0.009 |
Laboratory findings | |||
CPK, U/l | 1649 (740–2699) | 3473 (2544–4885) | 0.011 |
CK-MB, U/l | 159 (62–273) | 371 (271–520) | 0.014 |
cTnI (μg/l) | 16 (3–45) | 7 (1–30) | 0.62 |
Total cholesterol, mmol/l | 5.9 (5.2-7.2) | 6.2 (5.6-6.8) | 0.78 |
LDL cholesterol, mmol/l | 3.9 (3.2-4.8) | 3.9 (3.4-4.4) | 0.93 |
HDL cholesterol, mmol/l | 1.4 (1.2-1.7) | 1.3 (1.1-1.7) | 0.64 |
Triglycerides, mmol/l | 1.5 (1.1-2.2) | 1.6 (0.9-2.6) | 0.93 |
Glucose, mmol/l | 6.4 (5.6-7.7) | 9.3 (7.3-14.1) | 0.002 |
CRP (mg/l) | 2.2 (0.7-6.3) | 2.0 (1.3-6.0) | 0.74 |
Creatinine, μmol/l | 84 (73–96) | 94 (74–127) | 0.26 |
IL-6, pg/ml | 2.0 (0.1-9.0) | 8.5 (2.5-20.0) | 0.032 |
sIL-6R, ng/ml | 53.0 (41.6-66.2) | 51.1 (32.9-65.1) | 0.58 |